Premium
The Impact of Personality Disorders on Alcohol‐Use Outcomes in a Pharmacotherapy Trial for Alcohol Dependence and Comorbid Axis I Disorders
Author(s) -
Ralevski Elizabeth,
Ball Samuel,
Nich Charla,
Limoncelli Diana,
Petrakis Ismene
Publication year - 2007
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1080/10550490701643336
Subject(s) - naltrexone , disulfiram , borderline personality disorder , alcohol dependence , placebo , alcohol use disorder , personality disorders , psychiatry , context (archaeology) , antisocial personality disorder , pharmacotherapy , alcohol , psychology , craving , clinical psychology , comorbidity , personality , medicine , poison control , injury prevention , addiction , pharmacology , opioid , emergency medicine , chemistry , alternative medicine , receptor , pathology , biology , social psychology , paleontology , biochemistry
Although antisocial and borderline personality disorders frequently co‐occur with alcohol dependence and other Axis I disorders, their effect on alcohol use outcomes in context of pharmacotherapy remains unclear. Patients with Major Axis I disorders, including alcohol dependence, and diagnosis of antisocial (ASPD) or borderline personality disorder (BPD) were enrolled in a 12‐week medication trial for treatment of their alcohol dependence. Everyone was randomized to one of four cells: naltrexone alone, placebo alone, open label disulfiram and naltrexone, or open label disulfiram and placebo. Outcome measures included scales for alcohol use and craving. Data were analyzed comparing patients with ASPD vs. those without, and patients with BPD vs. those without. Diagnosis of personality disorder did not adversely affect alcohol outcomes, and patients with ASPD or BPD did not have a poorer response to medication than patients without diagnosis of ASPD or BPD. The findings suggest that naltrexone and disulfiram can be safely and effectively used with patients who have comorbid diagnoses of Axis I and Axis II disorders.